Yes it's a bit of a concern that a direct question related to our ongoing studies was not answered. May be someone can email Pat and she may be able to forward this up to the speaker.
I am not great at medical communication, hence I will leave it to someone else if they can.
Also, not defending any one here but looks like the company priority is EMA trials and looks like they are not interested in anything else at the moment even though PPMD is equally important...
I think management believes that if EMA goes well, it will open up US automatically..
subject to toxic outcomes...
Other indications, page-23
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |